Study of HY001N for hard-to-treat neurological autoimmune diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-stage trial tests a new CAR-T cell therapy called HY001N for people with hard-to-treat neurological autoimmune diseases like NMOSD, myasthenia gravis, MS, and others. It aims to see if targeting B cells can help when standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a specific neurological autoimmune disease such as NMOSD, myasthenia gravis, CIDP, multiple sclerosis, autoimmune encephalitis, or MOGAD.
- Your disease must still be active despite trying standard treatments, or you cannot take those treatments.
- You must have adequate organ function, including blood counts, liver, kidney, and heart health.
- You must agree to use effective birth control during and for 24 months after treatment (if applicable).
- You cannot have active infections, certain viruses (like HIV, hepatitis B/C), recent major surgery, or a history of certain cancers or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
Hear when a new Neurological Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.